Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today ...

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive ...

Sanofi-owned biotech company Genzyme has sued rival Sarepta Therapeutics in Delaware federal court for allegedly infringing two patents related to Sarepta's Duchenne muscular dystrophy (DMD ...

No articles found. Genzyme Corporation did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are wholly ...

Counsel have not yet appeared for the defendant. The case is 2024CV030484, Genzyme Corp et al v. Graesser Bzdek, Kristin. Biotech & Pharmaceuticals February 15, 2024, 10:03 PM ...

Genzyme Corp spent $2,652,000 lobbying in 2010. See the lobbyists it hired.

Beginning as a startup in downtown Boston with a mere handful of employees, Genzyme now has revenues of $4 billion, with offices and laboratories in more than 40 nations. In 2011, the French drug ...

Cambridge-based biotech Genzyme Corp. will be paying a $32.5 million settlement to resolve allegations that it inappropriately marketed a surgical device. According to a release from the U.S ...

(Reuters) - Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant ...

How Genzyme became a source of biotech executives By Robert Weisman Globe Staff,July 11, 2015, 8:32 p.m.

By Emily Micucci Cambridge-based Genzyme Corp. will move part of its operations in Framingham to Westborough by the end of the year, taking with it 500 employees, the company said.